AKAmelia KęDziora

Amelia KęDziora

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amelia KęDziora has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    INDOCYANINE GREEN FLUORESCENCE IN ONCOLOGIC SURGERY: A CRITICAL REVIEW OF SENTINEL LYMPH NODE MAPPING AND TUMOR MARGIN ASSESSMENT

    by Amelia KęDziora, Kinga Haduch, Zuzanna Michalska, Olga Chorąży, Aleksandra Stańczyk, Anna ŁęCzycka, Kinga Stefańska, Nicole Aleksandra Ordyczyńska-Mardyła, Izabela Zuzanna Stranz, Joanna Strzelczyk, et al.

    Objective: To critically evaluate current evidence regarding the clinical utility, effectiveness, and limitations of indocyanine green (ICG) fluorescence imaging in oncologic surgery, with particular emphasis on sentinel lymph node mapping and tumor margin assessment. Methods: A narrative literature review was conducted using the PubMed database. Studies published between 2013 and 2025 were analyzed, including clinical studies, randomized trials, systematic reviews, meta-analyses, consensus statements, and methodological papers addressing oncologic applications of ICG fluorescence imaging. Results: Strong evidence supports the use of ICG fluorescence imaging in sentinel lymph node mapping across colorectal, gastric, breast, and gynecologic cancers. The technique improves visualization of lymphatic pathways and facilitates intraoperative navigation. Evidence regarding tumor margin assessment remains heterogeneous, with diagnostic performance limited by the non-specific accumulation of ICG and variability among imaging protocols. Conclusions: ICG fluorescence imaging is an effective and increasingly valuable tool in oncologic surgery, particularly for sentinel lymph node mapping. However, its role in tumor margin assessment remains less established. Further standardization and development of tumor-specific fluorescence agents are required to optimize clinical applications.

  • Open Access

    CO-OCCURRENCE OF ASTHMA AND ANXIETY-DEPRESSIVE DISORDERS – CLINICAL IMPLICATIONS. A NARRATIVE REVIEW 2019-2026

    by Olga Chorąży, Zuzanna Michalska, Anna ŁęCzycka, Kinga Haduch, Nicole Aleksandra Ordyczyńska-Mardyła, Izabela Zuzanna Stranz, Aleksandra Stańczyk, Joanna Strzelczyk, Amelia KęDziora, Iga Suchta

    Introduction: Asthma is one of the most common chronic diseases worldwide, and its course may be significantly influenced by psychological factors. Anxiety and depressive disorders are among the most frequent comorbidities in patients with asthma. Aim: The aim of this study was to analyze the coexistence of asthma and anxiety-depressive disorders, with particular emphasis on symptoms, pathophysiological mechanisms, and clinical implications. Materials and Methods: A narrative literature review was conducted using the PubMed database. Publications published between January 2019 and July 21, 2026 were searched using the keywords: “asthma”, “anxiety”, and “depression”. Results: Anxiety disorders were found to occur in approximately 24–35% of patients with asthma, while depression affected 12–27% of this population. The coexistence of these disorders is associated with poorer disease control, more frequent exacerbations, reduced quality of life, and diagnostic difficulties resulting from overlapping symptoms. Both biological mechanisms, including chronic inflammation and dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, as well as psychological factors, play an important role. Conclusions: Anxiety and depressive disorders constitute an important component of the clinical picture of asthma and should be routinely considered in clinical practice. A comprehensive therapeutic approach may improve disease control and patients’ quality of life.

  • Open Access

    ARTIFICIAL INTELLIGENCE IN MODERN MEDICINE: A COMPREHENSIVE REVIEW OF CURRENT APPLICATIONS, CHALLENGES, AND FUTURE PERSPECTIVES

    by Aleksandra Stańczyk, Kinga Haduch, Zuzanna Michalska, Anna ŁęCzycka, Nicole Aleksandra Ordyczyńska-Mardyła, Izabela Zuzanna Stranz, Olga Chorąży, Joanna Strzelczyk, Iga Suchta, Amelia KęDziora

    Introduction: The digital transformation of healthcare is accelerating, driven by unprecedented advancements in Artificial Intelligence (AI). From large language models (LLMs) to biomolecular structure prediction, AI is redefining modern diagnostic and therapeutic standards. Aim: This review evaluates the current state of AI applications in medicine, focusing on clinical knowledge encoding, molecular drug discovery, and administrative workflow optimization, while critically addressing the technical, ethical, and systemic challenges of their institutional implementation. Materials and Methods: A structured analysis was conducted utilizing a hybrid approach that combines a multi-decade bibliometric trend perspective with a detailed synthesis of 21 landmark publications, clinical trials, and meta-analyses from high-impact journals. Results: AI demonstrates expert-level performance in medical knowledge retrieval and spatiotemporal diagnostics. AlphaFold 3 has revolutionized computational therapeutics through all-atom biomolecular interaction prediction, while ambient AI scribes significantly reduce physician burnout by automating clinical documentation workflows. However, data-driven "hallucinations" in LLMs and the inherent "black box" nature of deep learning architectures remain critical barriers to autonomous deployment. Conclusions: AI is successfully transitioning from an isolated research tool into an essential clinical "co-pilot." Achieving its full potential in Medicine 4.0 requires robust frameworks for algorithmic explainability, global dataset diversification, and a strategic synergy between machine precision and human clinical judgment.

  • Open Access

    ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN PERIMENOPAUSAL WOMEN: THE IMPACT OF HORMONAL CHANGES ON SYMPTOM SEVERITY AND CLINICAL IMPLICATIONS – A LITERATURE REVIEW

    by Nicole Aleksandra Ordyczyńska-Mardyła, Anna ŁęCzycka, Kinga Haduch, Zuzanna Michalska, Izabela Zuzanna Stranz, Aleksandra Stańczyk, Olga Helena Chorąży, Joanna Strzelczyk, Iga Suchta, Amelia KęDziora

    Background: Attention-Deficit/Hyperactivity Disorder (ADHD) is increasingly recognized as a lifelong condition; however, the impact of the menopausal transition on its symptomatic trajectory remains significantly under-researched. In females, ADHD is frequently masked by compensatory mechanisms until midlife, leading to diagnostic delays. This review examines the neurobiological and clinical intersection between fluctuating ovarian steroids and ADHD pathophysiology. Methods: A narrative synthesis of 20 selected scientific sources was conducted, incorporating neuroendocrinological reviews, clinical cohort studies, neuroimaging data, and qualitative research. Results: Evidence indicates a "double whammy" effect from the convergence of neurodevelopmental dopamine deficiency and perimenopausal estrogen withdrawal. 17β-estradiol acts as a critical neuromodulator of dopaminergic and serotonergic systems, exerting neuroprotective effects on the prefrontal cortex. Its decline during perimenopause unmasks previously latent ADHD symptoms, exacerbating executive dysfunction ("brain fog"), inattention, and emotional dysregulation. Women with hormone-related mood disorders such as PMDD exhibit heightened vulnerability. Additionally, "diagnostic overshadowing" frequently occurs, whereby ADHD symptoms are misattributed to menopausal depression or anxiety. The analysis highlights the efficacy of lisdexamfetamine in mitigating cognitive deficits in this demographic. Conclusions: The menopausal transition represents a period of significant clinical vulnerability for women with ADHD. Optimizing outcomes requires individualized, interdisciplinary strategies integrating stimulant pharmacotherapy with Hormone Replacement Therapy (HRT) and gender-sensitive psychoeducation. Future longitudinal research is essential to establish standardized clinical guidelines.

  • Open Access

    VITAMIN D AND RESPIRATORY TRACT INFECTIONS: A NARRATIVE REVIEW OF DEFICIENCY, SUPPLEMENTATION STRATEGIES, AND CLINICAL OUTCOMES

    by Iga Suchta, Nicole Aleksandra Ordyczyńska-Mardyła, Anna ŁęCzycka, Kinga Haduch, Zuzanna Michalska, Izabela Zuzanna Stranz, Aleksandra Stańczyk, Olga Helena Chorąży, Joanna Strzelczyk, Amelia KęDziora

    Vitamin D is widely recognised for its role in calcium homeostasis and skeletal health, yet its biological relevance extends beyond the musculoskeletal system to immune regulation and host defence. Over the past decade, the relationship between vitamin D status and respiratory tract infections (RTIs) has attracted increasing scientific interest, particularly in the context of the widespread prevalence of vitamin D deficiency and the global impact of the COVID-19 pandemic. This narrative review synthesises evidence on vitamin D deficiency, supplementation strategies, and respiratory clinical outcomes, drawing on randomised controlled trials, systematic reviews, meta-analyses, observational studies, and selected mechanistic publications. The reviewed literature consistently suggests that low serum 25-hydroxyvitamin D [25(OH)D] concentrations are associated with increased susceptibility to RTIs and, in many settings, with poorer respiratory outcomes. However, evidence regarding the benefits of supplementation remains heterogeneous. Earlier meta-analyses suggested modest protective effects, particularly among individuals with lower baseline vitamin D status and in studies using daily or weekly standard-dose regimens, whereas more recent large randomised trials and updated meta-analyses have reported smaller, inconsistent, or statistically non-significant overall effects. These discrepancies likely reflect variation in study population, baseline deficiency, supplementation regimen, trial duration, and outcome definition. Current evidence does not support a universal preventive or therapeutic role of vitamin D supplementation for all RTIs, but it strongly supports the importance of identifying and correcting deficiency, particularly in high-risk groups. From a wider perspective, vitamin D deficiency should also be understood as a socially patterned and potentially modifiable determinant of health, with relevance to prevention, health equity, and public health planning.

  • Open Access

    CLINICAL APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN MODERN HEMATOLOGY: DIAGNOSTIC AND PROGNOSTIC PERSPECTIVES

    by Joanna Strzelczyk, Amelia KęDziora, Olga Chorąży, Aleksandra Stańczyk, Nicole Aleksandra Ordyczyńska-Mardyła, Zuzanna Michalska, Kinga Haduch, Anna ŁęCzycka, Izabela Zuzanna Stranz, Iga Suchta

    Artificial intelligence (AI) has recently emerged as an important tool supporting diagnostics and clinical decision-making across multiple fields of medicine, including hematology. Rapid advances in machine learning algorithms and computational data analysis have enabled the processing and interpretation of complex biomedical datasets derived from laboratory diagnostics, medical imaging, and molecular studies [1,2]. These developments are particularly relevant in hematology, where the interpretation of large volumes of morphological, immunophenotypic, and genetic data plays a crucial role in disease diagnosis and monitoring. In hematological practice, artificial intelligence has demonstrated promising applications in the automated analysis of peripheral blood smears and bone marrow aspirates, as well as in the interpretation of flow cytometry data and molecular diagnostic results [3,4]. Several studies have shown that AI-based systems can achieve high levels of sensitivity and specificity in the detection of abnormal cellular populations, including leukemic blasts, potentially improving diagnostic accuracy and reducing the time required for laboratory evaluation [5]. Despite these promising developments, the clinical implementation of artificial intelligence in hematology remains associated with several challenges, including the need for large, high-quality training datasets, external validation across different patient populations, and integration with existing laboratory information systems [6]. The aim of this article is to review the current state of knowledge regarding the use of artificial intelligence in hematology, with particular emphasis on its applications in laboratory diagnostics, microscopic image analysis, and prognostic modeling in hematological diseases.

  • Open Access

    PHARMACOTHERAPY IN MUSCLE DYSMORPHIC DISORDER: CLINICAL CONSIDERATIONS AND THE LIMITS OF EXTRAPOLATING EVIDENCE FROM BODY DYSMORPHIC DISORDER

    by Anna ŁęCzycka, Kinga Łysak, Kinga Haduch, Zuzanna Michalska, Nicole Aleksandra Ordyczyńska-Mardyła, Izabela Zuzanna Stranz, Aleksandra Stańczyk, Olga Chorąży, Joanna Strzelczyk, Amelia KęDziora, et al.

    Background: Muscle dysmorphic disorder is a specifier of body dysmorphic disorder (BDD) characterized by a tenacious belief of insufficient muscularity. Although currently classified within BDD, muscle dysmorphism exhibits distinct clinical and behavioral features, constituting compulsive exercise, rigid dietary practices, and use of performance-enhancing substances. Aforementioned differences raise concerns regarding applicability of pharmacotherapeutic strategies derived from BDD studies to patients with muscle dysmorphism. The aim of the study is to critically evaluate the existing literature on pharmacotherapy in body dysmorphic disorder and assess its clinical applicability to muscle dysmorphic disorder, with considerations of diverging neurobiological, phenomenological, and behavioral distinction limiting direct generalizability. Methods: A broad literature search was conducted in three major databases: PubMed, Cochrane Library, and Google Scholar, utilizing search terms (“muscle dysmorphism” or “muscle dysmorphic disorder” or “bigorexia nervosa” or “body dysmorphic disorder”) and (“pharmacotherapy” or “treatment” or “medication” or “pharmaceutical”). References were screened for relevance, and a total of 20 studies published between 1996 and 2026 were included in the analysis. Results: This review evaluates and summarizes established pharmacological strategies used in the treatment of BDD and examines their potential relevance for muscle dysmorphic disorder. Selective serotonin reuptake inhibitors (SSRIs) remain the most consistently supported pharmacological intervention, demonstrating meaningful reductions in symptom severity across several studies. Additional treatments, including clomipramine and serotonin–noradrenaline reuptake inhibitors, have shown potential benefits in selected cases. Emerging therapeutic approaches, such as glutamatergic modulators, intranasal oxytocin, and psychedelic-assisted therapy, remain experimental. However, no clinical trials have specifically examined pharmacotherapy in muscle dysmorphic disorder. Conclusions: Pharmacological strategies developed for BDD may provide partial therapeutic benefit, important differences in clinical presentation and potential neurobiological mechanisms limit direct extrapolation to muscle dysmorphic disorder. Future research should prioritize clinically controlled randomized trials exploring targeted pharmacological treatments for this condition.

  • Open Access

    PSYCHIATRIC COMORBIDITIES IN ATOPIC DERMATITIS – A NARRATIVE REVIEW FOCUSING ON DEPRESSION AND ANXIETY

    by Izabela Zuzanna Stranz, Anna ŁęCzycka, Kinga Haduch, Zuzanna Michalska, Nicole Aleksandra Ordyczyńska - Mardyła, Aleksandra Stańczyk, Olga Chorąży, Joanna Strzelczyk, Amelia KęDziora, Iga Suchta

    Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, affecting both children and adults worldwide. Beyond its dermatological manifestations, AD often leads to sleep disturbances, persistent itch, and discomfort, which may contribute to elevated levels of anxiety and depression. The disease’s relapsing course and visible skin lesions can further impact social functioning and quality of life, highlighting the need to understand its psychological burden. This review aims to summarize current evidence on the impact of pruritus and sleep disturbances on depression and anxiety in patients with atopic dermatitis, explore potential biological mechanisms, and discuss their effects on patients’ quality of life and clinical implications. Methods: A narrative literature review was conducted using PubMed and Google Scholar, including original studies, population-based analyses, clinical trials, and relevant reviews addressing psychological outcomes in both paediatric and adult populations. Results: Depression and anxiety are among the most common psychiatric comorbidities in AD, with prevalence estimates showing considerable variability across studies. Their occurrence and severity are closely associated with disease severity, chronic pruritus, and sleep disturbances. Pruritus and sleep disruption emerge as key mediators linking dermatological symptoms with psychological distress. In addition to psychosocial factors such as visible skin lesions and social stigma, biological mechanisms—including immune dysregulation, increased pro-inflammatory cytokine activity, and alterations of the hypothalamic–pituitary–adrenal axis—may contribute to increased vulnerability to mood disorders. Conclusions: Despite the high prevalence of psychiatric symptoms, mental health assessment remains insufficiently integrated into routine AD care. Early identification and multidisciplinary management are essential. Future research should focus on prospective studies evaluating integrated therapeutic approaches to improve both mental health outcomes and overall quality of life in patients with AD.

  • Open Access

    Aesthetic medicine as a tool for improving well-being, body image perception, and social functioning from a psychosocial perspective - review

    by Kinga Haduch, Zuzanna Michalska, Anna ŁęCzycka, Nicole Aleksandra Ordyczyńska-Mardyła, Izabela Zuzanna Stranz, Aleksandra Stańczyk, Olga Chorąży, Joanna Strzelczyk, Amelia KęDziora, Iga Suchta

    Aesthetic medicine is one of the fastest-growing areas of contemporary medicine and lies at the intersection of medical sciences, psychology, sociology, and cultural studies. The increasing popularity of aesthetic procedures results not only from technological progress and greater accessibility of treatments, but also from changing social expectations regarding physical appearance. The aim of this study is to analyze aesthetic medicine as a tool influencing psychological well-being, self-image perception, and the social functioning of individuals, taking into account psychological, cultural, generational, and ethical aspects. The article discusses the significance of aesthetic procedures in the context of patients’ self-esteem and quality of life, as well as the influence of cultural norms and mass media on the formation of contemporary standards of beauty. Particular attention is devoted to generational differences in attitudes toward aesthetic procedures and to the role of digital media in shaping expectations regarding appearance. The article also emphasizes the importance of ethical principles in aesthetic medicine practice, including respect for patient autonomy, the necessity of obtaining informed consent, and the physician’s responsibility for ensuring patient safety and maintaining realistic expectations regarding treatment outcomes. Furthermore, the relationship between the use of aesthetic procedures and mental health is examined, with particular emphasis on body dysmorphic disorder (BDD) and other psychological conditions that may influence patients’ motivations. The results of the analysis indicate the need for careful patient selection and the implementation of an interdisciplinary approach involving collaboration between aesthetic medicine specialists, psychologists, and psychiatrists. Such an approach may facilitate the achievement of positive therapeutic outcomes while reducing the risk of unjustified or potentially harmful interventions.